Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Capital Expenditures (2024 - 2025)

Beta Bionics (BBNX) has disclosed Capital Expenditures for 2 consecutive years, with $5.3 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 837.43% to $5.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.3 million through Dec 2025, up 56.02% year-over-year, with the annual reading at $5.3 million for FY2025, 56.02% up from the prior year.
  • Capital Expenditures hit $5.3 million in Q4 2025 for Beta Bionics, up from -$2.1 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $5.3 million in Q4 2025 to a low of -$2.1 million in Q3 2025.